Lymphoma Research Foundation awards over $5.7M in grants

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo

A new first-line treatment involving the PD-1 inhibitor nivolumab for advanced-stage classic Hodgkin lymphoma could soon make its way into clinics.

October 18, 2024

Vol.50 No.39

By McKenzie Prillaman

In Brief

Qure.ai completes $65M Series D funding round

Qure.ai has announced the completion of a $65 million Series D funding round. The investment will expedite expansion into the U.S. market and other countries, increase investment in foundational AI models, and enable complementary med-tech company acquisitions.

October 04, 2024

Vol.50 No.37

Guest Editorial

Group chairs propose funding strategy to jump-start correlative studies

The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.”

September 20, 2024

Vol.50 No.35

By Peter J. O'Dwyer

Funding Opportunities

DOD Glioblastoma Research Program funding opportunities for FY24

The FY24 Defense Appropriations Act provides funding for the Glioblastoma Research Program to support research of high potential impact and exceptional scientific merit to reduce the burden of glioblastoma on service members and their families, veterans, and the American public. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.

September 20, 2024

Vol.50 No.35

Conversation with The Cancer Letter

A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease

City of Hope has received a $150 million gift from entrepreneurs and philanthropists A. Emmet Stephenson Jr. and his daughter Tessa Stephenson Brand to create a program focused on pancreatic cancer research.

From clinician scientist to nonprofit CEO

I was a practicing pediatric hematologist oncologist and researcher for 21 years. As a doctor, it was a tremendous privilege to be invited into the lives of patients and families dealing with blood cancers and be entrusted with their care. As a researcher, it was incredibly rewarding to help bring more effective blood cancer therapies to kids.

September 13, 2024

Vol.50 No.34

By E. Anders Kolb

Lymphoma Research Foundation awards over $5.7M in grants

YOU MAY BE INTERESTED IN

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo

Qure.ai completes $65M Series D funding round

Group chairs propose funding strategy to jump-start correlative studies

DOD Glioblastoma Research Program funding opportunities for FY24

A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease

From clinician scientist to nonprofit CEO

Renew today!

Subscriber content

Login

Lymphoma Research Foundation awards over $5.7M in grants

YOU MAY BE INTERESTED IN

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?Phase III trial finds improved PFS, side effects with nivolumab+chemo

Qure.ai completes $65M Series D funding round

Group chairs propose funding strategy to jump-start correlative studies

DOD Glioblastoma Research Program funding opportunities for FY24

A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease

From clinician scientist to nonprofit CEO

Login

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo